The board of directors of US drugmaker Schering-Plough has announced four new measures, which it says are designed to demonstrate the firm's commitment to improving its corporate governance. The board added that the move will replace long-standing busniess practices that have been in place at the firm since before the arrival of the new management team in spring 2003.
The four steps are: the termination of the existing shareholders rights plan, which allows existing shareholders to purchase newly-issued shares during a hostile takeover; a major reduction in shareholder voting requirments on key decisions; a system of directorial elections that allows for selection by a majority of votes cast versus a plurality of shareholder votes cast; and expedition the previously approved change providing for the annual election of directors.
Fred Hassan, chairman of the firm's board, said: "we believe it is important to stay in tune with the expectations of our shareowners and our evolving environment." He added that the measures will aid the development of the company as a high-performance organization in the long term.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze